A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis
Journal of Rheumatic Diseases
;
: 361-363, 2013.
Article
Dans Anglais
| WPRIM
| ID: wpr-173304
ABSTRACT
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFalpha) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFalpha agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFalpha agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pelvispondylite rhumatismale
/
Immunoglobuline G
/
Pharmacocinétique
/
Anti-inflammatoires non stéroïdiens
/
Dialyse péritonéale
/
Facteur de nécrose tumorale alpha
/
Récepteurs aux facteurs de nécrose tumorale
/
Antirhumatismaux
/
Insuffisance rénale
/
Étanercept
Limites du sujet:
Adulte
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Journal of Rheumatic Diseases
Année:
2013
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS